What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?

During the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Robert Zeiser, Medical Center - University of Freiburg, Freiburg, DE. We asked, What is the latest data from REACH-3 for ruxolitinib treated patients with steroid refractory chronic graft versus host disease (SR-cGvHD) after crossover?
Zeiser begins by explaining the motivation behind REACH-3 and goes on to outline its study design. He then provides insights on the efficacy and tolerability data presented at the 49th Annual Meeting of the EBMT, including response rates and comparisons with existing safety profiles. Zeiser concludes by detailing the applications of ruxolitinib in patients with steroid refractory chronic GvHD who have not responded to other systemic therapies.
More information on the REACH-3 clinical trial can be found on the GvHD Hub.

[@amiramiri9245]

appreciate for this Informant video Professor Zeiser